FierceBiotech (@FierceBiotech) header
FierceBiotech (@FierceBiotech) profile picture

FierceBiotech

@FierceBiotech

The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.

 Washington, DC
FierceBiotech.com
Joined December 2008
  • Tweets29.8K
  • Following614
  • Followers103K
170Media
Photo by FierceBiotech (@FierceBiotech)Photo by FierceBiotech (@FierceBiotech)Photo by FierceBiotech (@FierceBiotech)Photo by FierceBiotech (@FierceBiotech)Photo by FierceBiotech (@FierceBiotech)Photo by FierceBiotech (@FierceBiotech)Photo by FierceBiotech (@FierceBiotech)Photo by FierceBiotech (@FierceBiotech)Photo by FierceBiotech (@FierceBiotech)Photo by FierceBiotech (@FierceBiotech)
FierceBiotech retweeted
FiercePharma (@FiercePharma) profile picture
FiercePharma
@FiercePharmaOct 28
Enhertu has transformed HER2 breast cancer treatment and set a high bar for the next generation of drugs. Now, the race is on to develop something even better, but finding a worthy successor is proving to be easier said than done. fiercebiotech.com/biotech/ad…
As ADC king Enhertu rewrites HER2 breast cancer care, the hunt for what comes next is barely out...

As ADC king Enhertu rewrites HER2 breast cancer care, the hunt for what comes next is barely out...

Shortly after Jazz Pharmaceuticals licensed the HER2-targeted bispecific antibody zanidatamab from Zymeworks in 2022, Rob Iannone, M.D., received a flood of phone calls from breast cancer researchers...

fiercebiotech.com
2
4
16
3,348
FierceBiotech retweeted
FiercePharma (@FiercePharma) profile picture
FiercePharma
@FiercePharmaOct 23
🎧 This week on "The Top Line": GSK's pair of FDA approvals, Roche's $15 billion ADC deal and the rise of point-of-care pharma marketing. fiercepharma.com/pharma/gsks…
GSK's double FDA win, Roche's $15B deal and the rise of point-of-care marketing

GSK's double FDA win, Roche's $15B deal and the rise of point-of-care marketing

In this week's episode of "The Top Line," we're covering a pair of FDA approvals for GSK, an antibody-drug conjugate pact worth up to $15 billion and the growing role of poin | This week on "The Top...

fiercepharma.com
2
1
5
2,196
FierceBiotech retweeted
FiercePharma (@FiercePharma) profile picture
FiercePharma
@FiercePharmaAug 14
Today on “The Top Line”: Regeneron Genetics Center’s Andy Deubler sits down with Fierce’s Fraiser Kansteiner to discuss how RGC’s massive genetics database is helping validate drug targets, what sets its data apart and how it could play a role in AI-powered drug development. omny.fm/shows/the-top-line/a…
A genomics library for the AI era - The Top Line

A genomics library for the AI era - The Top Line

Having spent 14 years building out its capacity, Regeneron Genetics Center—the genomic research branch of the Tarrytown, New York-based pharma—is a pro when it comes to the sort of target validation...

omny.fm
4
12
3,553
FierceBiotech retweeted
FiercePharma (@FiercePharma) profile picture
FiercePharma
@FiercePharmaAug 6
Narcan maker Emergent BioSolutions eliminates top R&D role in sweeping restructuring fiercepharma.com/pharma/narc…
Narcan maker Emergent BioSolutions eliminates top R&D role in sweeping restructuring

Narcan maker Emergent BioSolutions eliminates top R&D role in sweeping restructuring

Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to align the business with “current business realities.” | Two and a half...

fiercepharma.com
3
6
3,423
FierceBiotech retweeted
FiercePharma (@FiercePharma) profile picture
FiercePharma
@FiercePharmaJul 31
🎧This week on "The Top Line": Psychedelics, peptides and GLP-1s fiercepharma.com/pharma/psyc…
Psychedelics, peptides and GLP-1s

Psychedelics, peptides and GLP-1s 

Is biotech taking a trip to the world of psychedelic drugs? Why is Novo Nordisk going after Eli Lilly’s Zepbound ads? | This week on “The Top Line,” Fierce’s Zoey Becker, Will Maddox and Kevin...

fiercepharma.com
2
6
3,080
FierceBiotech retweeted
FiercePharma (@FiercePharma) profile picture
FiercePharma
@FiercePharmaMay 15
Despite prolonged policy uncertainty in the U.S., many healthcare and life sciences execs are still seeing opportunities amid the tumult. On “The Top Line,” Fierce Pharma's Fraiser Kansteiner talks with @PwC's U.S. health industries leader about tariffs, drug pricing reform, AI and the future of U.S. healthcare innovation. fiercepharma.com/pharma/heal…
Health execs persevere in new policy landscape

Health execs persevere in new policy landscape

Despite a prolonged period of policy uncertainty in the U.S.—and the ripple effects across the global life sciences and healthcare industries—executives at health companies are still seeing opportu |...

fiercepharma.com
4
8
2,279
FierceBiotech retweeted
FierceBiotech (@FierceBiotech) profile picture
FierceBiotech
@FierceBiotechApr 3
The number of drugs in development has fallen for the first time since the mid-1990s fiercebiotech.com/biotech/bi…

Biopharma R&D pipeline shrinks for 1st time in 30 years: report

The number of drugs in development has fallen for the first time since the mid-1990s, according to a Citeline report. | The number of drugs in development has fallen for the first time since the...

fiercebiotech.com
1
8
2
23
6,927
FierceBiotech retweeted
FiercePharma (@FiercePharma) profile picture
FiercePharma
@FiercePharmaApr 3
🎧 This week on "The Top Line": a look at pharma’s reshoring push, where it stands and what comes next. fiercepharma.com/pharma/upda…
An update on the pharma industry’s reshoring effort

An update on the pharma industry’s reshoring effort

After a wave of high-profile pledges to bring pharmaceutical manufacturing back to the United States, a clearer picture of what reshoring actually looks like is star | Where does pharma’s reshoring...

fiercepharma.com
1
1
8
2,330
FierceBiotech retweeted
FiercePharma (@FiercePharma) profile picture
FiercePharma
@FiercePharmaFeb 2
Special report: Top 10 most anticipated drug launches of 2026 fiercepharma.com/marketing/t…
Top 10 most anticipated drug launches of 2026

Top 10 most anticipated drug launches of 2026

Like last year, 2026 appears poised to herald the arrival of multiple mega-blockbusters—albeit on an even grander scale than 2025’s plenty-respectable slate of major rollouts.According to Evaluate’s...

fiercepharma.com
1
7
1
33
13,219
FierceBiotech retweeted
Pearl Freier (@PearlF) profile picture
Pearl Freier
@PearlFJan 20
Here's a link to the ARPA-H story in @FierceBiotech fiercebiotech.com/research/a…
ARPA-H director eyes future beyond vaccines, 'winning the biotech race' against China

ARPA-H director eyes future beyond vaccines, 'winning the biotech race' against China

The new leader of the Advanced Research Projects Agency for Health (ARPA-H), a Biden-era health innovation program that has remained intact despite President Donald Trump’s substantial cuts to fede |...

fiercebiotech.com
2
3
2,191
FierceBiotech retweeted
FierceHealthcare (@FierceHealth) profile picture
FierceHealthcare
@FierceHealthJan 15
BREAKING: Trump takes aim at insurance industry in unveiling 'The Great Healthcare Plan' bit.ly/49Iy9NH
3
4
4,415
FierceBiotech retweeted
FiercePharma (@FiercePharma) profile picture
FiercePharma
@FiercePharmaJan 6
3 biopharma CEOs explain why they are 'authentically optimistic' for 2026 fiercepharma.com/pharma/fier…
3 biopharma CEOs explain why they are 'authentically optimistic' for 2026

3 biopharma CEOs explain why they are 'authentically optimistic' for 2026

While policy shifts and leadership shakeups at institutions like the Food and Drug Administration dominated headlines in 2025, drugmakers would do well to sift through the noise and remain focused |...

fiercepharma.com
2
3
10
4,745
FierceBiotech retweeted
FiercePharma (@FiercePharma) profile picture
FiercePharma
@FiercePharma19 Dec 2025
9 pharma giants reach US drug price deals with Trump administration fiercepharma.com/pharma/top-…
9 pharma giants reach US drug price deals with Trump administration

9 pharma giants reach US drug price deals with Trump administration

Nine large pharma companies have reached agreements with the Trump administration to lower certain drug prices in the U.S. | Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Gilead Sciences, GSK,...

fiercepharma.com
3
5
1
24
14,037
FierceBiotech retweeted
FiercePharma (@FiercePharma) profile picture
FiercePharma
@FiercePharma19 Dec 2025
🎧 In this special year-end episode of "The Top Line," Fierce reporters take stock of 2025 and look ahead to the trends and questions that will shape 2026. fiercepharma.com/pharma/year…
A year in review and what 2026 holds for biopharma and healthcare

A year in review and what 2026 holds for biopharma and healthcare

As 2025 closes, biopharma and healthcare are learning to live on shifting ground. | Fierce reporters break down the forces that shaped biopharma and healthcare in 2025 and what lies ahead in 2026.

fiercepharma.com
1
3
8
3,263
It's that time of year again... Fierce Biotech's Rotten Tomatoes of 2025 The @FierceBiotech team highlights some key strategic missteps, chaotic management or just rotten luck in the past year fiercebiotech.com/special-re…
Fierce Biotech's Rotten Tomatoes of 2025

Fierce Biotech's Rotten Tomatoes of 2025

There’s never a dull year in biotech. From waves of layoffs to a tepid IPO environment and big biobucks obesity deals, some of this year’s themes generated a sense of déjà vu. Other upheavals, such...

fiercebiotech.com
7
16
8,027
The FDA is continuing its push to adopt emerging artificial intelligence tools, this time unveiling an agentic AI program that employees can choose to use in their work. fiercebiotech.com/ai-and-mac…
FDA adopts agentic artificial intelligence in latest push to infuse AI into agency

FDA adopts agentic artificial intelligence in latest push to infuse AI into agency

The FDA is continuing its push to adopt emerging artificial intelligence tools, this time unveiling an

fiercebiotech.com
2
2
1,820
Study: Recent NIH grant terminations have disrupted at least 383 clinical trials, collectively impacting more than 74,000 patients. From @FierceBiotech: fiercebiotech.com/research/n…
NIH grant cuts have disrupted hundreds of clinical trials, study finds

NIH grant cuts have disrupted hundreds of clinical trials, study finds

The second Trump administration has been defined by widespread cuts to federal spending, including at the National Institutes of Health (NIH). | The second Trump administration has been defined by...

fiercebiotech.com
7
1
6
2,523
FierceBiotech retweeted
FiercePharma (@FiercePharma) profile picture
FiercePharma
@FiercePharma17 Nov 2025
Special report: 2025's Fiercest Women in Life Sciences fiercepharma.com/pharma/2025…
2025's Fiercest Women in Life Sciences

2025's Fiercest Women in Life Sciences

Despite an ongoing ebb and flow in their representation at the highest levels of leadership, women continue to shatter glass ceilings.Even as the first female vice president in U.S. history left...

fiercepharma.com
2
4
4,194
FierceBiotech retweeted
FiercePharma (@FiercePharma) profile picture
FiercePharma
@FiercePharma19 Oct 2025
Akeso and Summit Tx's ivonescimab and chemo reduced the risk of progression or death by 40% compared with BeOne’s Tevimbra and chemo in Chinese patients with first-line squamous NSCLC, according to HARMONi-6 data at #ESMO25 fiercepharma.com/pharma/akes…
ESMO: Akeso, Summit's ivonescimab beats PD-1 in first chemo combo win in 1st-line NSCLC

ESMO: Akeso, Summit's ivonescimab beats PD-1 in first chemo combo win in 1st-line NSCLC

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in China, Akeso and Summit Therapeutics’ ivonescimab has shown it can del |...

fiercepharma.com
3
18
4,525
Great piece by @FierceBiotech @FiercePharma @AylaEllison | Unpacking the FDA transparency push on CRLs fiercebiotech.com/biotech/un…
Unpacking the FDA transparency push on CRLs

Unpacking the FDA transparency push on CRLs

The FDA made waves in early September when it announced a plan to publicly release complete response letters (CRLs) at the same time they are issued to sponsorin | The FDA made waves in early...

fiercebiotech.com
1
4
1,721
Load more